5-MeO-DMT Safety, Risks and Screening

5-MeO-DMT can cause intense psychological and physical effects. Safety depends on medical and psychiatric screening, a complete medication review, a controlled setting, continuous supervision, emergency readiness and follow-up care. This page provides general education, not medical advice or clearance for use. Under United States federal law, 5-MeO-DMT remains a Schedule I controlled substance.

A 2024 systematic review found three qualifying clinical trials involving 78 participants, with follow-up no longer than seven days and no serious adverse events reported. Later small, open-label studies also reported generally favorable short-term tolerability in carefully screened, medically monitored adults. These small studies cannot establish safety for every person, product, combination or setting.

Nausea, vomiting, headache, dizziness, tremor, sweating, restlessness, anxiety, fear, confusion, impaired coordination and temporary increases in blood pressure or heart rate have been reported. An abrupt loss of ordinary awareness can also create risks from falls, injury, aspiration, unsafe restraint or delayed recognition of a medical problem.

Severe events appear uncommon in small controlled trials, but those studies are too small to rule out rare harm. Potential emergencies include seizure, severe hypertension, loss of airway protection, aspiration, injury, extreme agitation, serotonin toxicity, prolonged psychosis or mania. A short experience can still create a serious emergency.

Call emergency services for collapse, seizure, trouble breathing, blue or gray lips, chest pain, inability to awaken, repeated vomiting while poorly responsive, very high temperature with rigidity or jerking, severe confusion or agitation, stroke-like symptoms, or immediate risk of self-harm or violence. In the United States, call 911. Poison Control is 1-800-222-1222.

A generic online checklist cannot safely clear a medication combination. Risk depends on the exact medication, dose, timing, health conditions and every other substance used. Include prescriptions, over-the-counter medicines, supplements, herbs and recreational substances. Never stop, taper, skip, add or change medication without the prescribing clinician.

MAO inhibitors and harmala alkaloids are a major interaction concern because they can slow 5-MeO-DMT metabolism and may increase or prolong exposure. Preclinical evidence and a fatal multi-substance case support strong caution, although they do not establish the risk of 5-MeO-DMT alone. “Natural” does not make a combination safe.

Evidence is limited and does not support a universal answer. A 2026 open-label study followed 12 screened participants who remained on stable doses of four SSRIs while receiving a standardized intranasal formulation under medical monitoring. No serious adverse events were reported. It did not test every SSRI, any SNRI, other products or unmonitored settings. Do not stop antidepressants on your own.

Direct 5-MeO-DMT interaction data for lithium are extremely limited. Reports involving lithium with other classic psychedelics have raised concern about seizures, so qualified medical review is essential. Direct evidence for stimulants, alcohol, opioids, sedatives, cannabis and many supplements is also limited. Uncertain evidence is not evidence of safety.

Modern trials commonly exclude people with psychotic disorders, bipolar I disorder, current high suicide risk, uncontrolled hypertension, significant heart disease, seizure disorders, serious medical illness, pregnancy or breastfeeding, unstable substance use, or interacting medications. Exclusion shows where evidence is limited and researchers have taken a precautionary approach.

Screening should cover complete medical, medication, supplement and substance histories; personal and family psychiatric history; suicide risk; recent sleep, illness and medication changes; capacity for informed consent; safe transportation and recovery plans; and access to qualified aftercare. It must identify when participation should be declined or postponed.

Ask who performs screening, who reviews medications, what causes a postponement or decline, how the substance is identified, who remains continuously present, what the emergency plan is, how quickly emergency services can arrive, what the touch and privacy policies are, and what follow-up is available. Guaranteed outcomes or pressure to hide medications are serious red flags.